6 lutego ruszyła próba kliniczna potencjalnego leku #remdisivir (lub #remdisvir) na 452 pacjentach w Wuhan
Given no specific antiviral therapy for 2019-nCoV infection and the ready availability of remdesvir as a potential antiviral agent, based on pre-clinical studies in SARS-CoV and MERS-CoV infections, this randomized, controlled, double blind trial will evaluate the efficacy and safety of remdesivir in patients hospitalized with severe 2019-nCoV respiratory disease.
Źródło: https://clinicaltrials.gov/ct2/show/NCT04257656?cond=remdesivir&draw=2&rank=1